
Please try another search
Kainos Medicine, Inc. engages in research and development of various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-cancer agent to treat acute myeloid leukemia, as well as small molecule immuno-oncology drugs that modulate anti-cancer abilities of immune cells. In addition, the company is involved in the discovery of a Hepatitis B drug. It has a collaboration agreement with Emmaus Life Sciences, Inc. for the preclinical development of IRAK4 inhibitor as potential anti-cancer drug. The company was founded in 2007 and is headquartered in Seongnam-si, South Korea.
Name | Age | Since | Title |
---|---|---|---|
Victor E. Marquez | - | - | Member of Scientific Advisory Board |
Jong Sik Lee | - | - | Member of Scientific Advisory Board |
Jaemoon Lee | 67 | - | Chief Business Officer, VP of Biology & Internal Director |
Stephen Frye | - | - | Member of Scientific Advisory Board |
Ki-Sub Lee | 75 | - | Chairperson, Co-Founder & CEO |
M. C. Kang | - | - | Member of Scientific Advisory Board |
Carrolee Barlow | 62 | - | Member of Scientific Advisory Board |
Kim Eunhee | - | - | Member of Scientific Advisory Board |
John J. Toole | 71 | - | Member of Scientific Advisory Board |
Suh Tae Hwan | - | - | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review